. 2017 Sep 6;8(55):93633–93643. doi: 10.18632/oncotarget.20674

Table 1. Comparison of baseline characteristics between metachronous (N=86) and synchronous (N=32) mRCC groups with exclude non-clear cell patients.

	Metachronous (N= 86)	Synchronous (N= 32)	P-value
Age (years)	58.73±10.63	57.31±11.39	0.528^a
Gender (male/female)	69/17 (80.2/19.8)	25/7 (78.1/21.9)	0.800^b
Nephrectomy	23 (27.4)	31 (100)	<0.001^c
Metastatectomy	19 (22.1)	4 (12.5)	0.303 ^c
TFI, ≥1yr/ <1yr	5/81 (5.8/94.2)	22/10 (68.8/31.3)	<0.001^b
Anemia	59 (68.6)	27 (84.4)	0.088^b
Hypercalcemia	11 (13.3)	4 (12.5)	1 ^c
Neutrophilia	13 (15.5)	9 (28.1)	0.120^b
Elevated LDH	20 (30.8)	6 (26.1)	0.793^b
KPS > 80 /≤ 80	83/3 (96.5/3.5)	32/0 (100/0)	0.559^c
Thrombocytosis	11 (12.8)	3 (9.4)	0.756 ^b
Creatinine	1.2±0.4	1.3±0.5	0.210
eGFR	72.6±21.0	70.7±22.2	0.667
Metastatic lesion
Lung	58 (67.4)	27 (84.4)	0.105 ^c
Liver	17 (19.8)	8 (25.0)	0.614 ^c
Lymph node	38 (44.2)	12 (37.5)	0.538 ^c
Bone	31 (36.0)	11 (34.4)	1.000 ^c
Brain	10 (11.6)	5 (15.6)	0.547 ^c
Heng, Intermediate risk	65 (75.6)	28 (87.5)	0.159 ^b
Poor risk	21 (24.4)	4 (12.5)
cT or pT stage, T1-T2/ T3-T4	42/22 (65.6/34.4)	9/15 (37.5/62.5)	0.017^b
cN or pN stage, N0/ N1/ Nx	30/19/15 (46.9/29.7/23.4)	0/11/0 (0/100/0)	<0.001^b
Fuhrman nuclear grade,
G1-G2/G3-G4	22/35 (38.6/61.4)	3/20 (13/87)	0.026 ^b
Treatment duration (Mos.)	7.44±10.05	11.96±14.69	0.116 ^a
Follow-up duration (Mos.)	59.3 (4.8-60.1)	61.3 (9.4-64.3)	0.075 ^d
Progression-free survival (Mos)	5.2 (1.0-60.4)	9.6 (1.0-62.0)	0.059 ^d
Overall survival (=Cancer specific survival, Mos.)	9.6 (1.0-62.3)	20.1 (1.5-87.2)	0.010 ^d
Survival/death	15/71 (17.4/82.6)	5/27 (15.6/84.4)	1^b

a: Student's t-test, b: Chi-square test, c: Fisher exact test, d: Log-rank test, TFI: Treatment free interval, KPS: Karnofsky performance status, mos: months.